The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, signed a contract option valued at about $13.4 million with Cytori Therapeutics Inc.
The executed option will fund Cytori's clinical trial of Cytori Cell Therapy to develop it as a medical countermeasure for thermal burn injury.
According to the company, the contract option increases the authority's overall commitment to Cytori technology to about $34.6 million.
The original contract retains two as-yet unfunded options valued at up to $68 million. The first option is written to support a clinical trial that could potentially follow the present clinical trial on Cytori Cell Therapy and lead to its U.S. FDA approval as a treatment for thermal burn injury.
The second option addresses additional preclinical work targeting application in thermal burn and radiation injury.